Advertisement

Therapeutic Aspects of Leukotriene Antagonists and Inhibitors

  • A. W. Ford-Hutchinson
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)

Abstract

The metabolism of arachidonic acid by the 5-lipoxygenase enzyme system results in the production of leukotrienes (Ford-Hutchinson, 1990a). 5-lipoxygenase is only present in cells of the myeloid lineage, including inflammatory cells such as polymorphonuclear leukocytes, eosinophils, mast cells and macrophages. Cellular activation induces a rise in intracellular calcium leading to an activation and translocation from the cytosol to the membrane fraction of both phospholipase A2 and 5-lipoxygenase (Rouzer and Kargman, 1988; Clark et al., 1991). Activation of 5-lipoxygenase is associated with the presence of a novel membrane protein, 5-lipoxygenase activating protein (FLAP) (Dixon et al., 1990; Miller et al., 1990). The end product of metabolism of arachidonic acid by the 5-lipoxygenase enzyme is leukotriene A4, an unstable epoxide intermediate. Further metabolism of leukotriene A4 can occur through, first, leukotriene A4 hydrolase, to produce the dihydroxy fatty acid, leukotriene B4, and, secondly, through leukotriene C4 synthase, to produce the glutathione conjugate, leukotriene C4 (Ford-Hutchinson, 1990a). Leukotriene C4 can then be converted to leukotriene D4 through loss of L-glutamic acid by the action of γ-glutamyl transferase. Leukotriene D4 in turn can be further metabolized by peptidases through loss of glycine to produce leukotriene E4.

Keywords

Allergic Conjunctivitis Human Bronchial Asthma Dihydroxy Fatty Acid Nonnal Volunteer Dimethylpropanoic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arm, J.P., Spur, B.W., and Lee, T.H., 1988, The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects, J.Allergy Clin. Immunol., 82: 654–660.PubMedCrossRefGoogle Scholar
  2. Bel, E.H., van der Veen, H., Kramps, J.A., Dijkman, J.H., and Sterk, P.J., 1987, Maximal airway narrowing to inhaled leukotriene D4 in normal subjects, Comparison and interaction with methacholine, Am.Rev.Respir.Dis., 136: 979–984.PubMedCrossRefGoogle Scholar
  3. Bel, E.H., Tanaka, W., Spector, R., Friedman, B., v.d. Veen, H., Dijkman, J.H., and Sterk, P.J., 1990, MK-886, an effective oral leukotriene biosynthesis inhibitor on antigen-induced early and late asthmatic reactions in man, Am.Rev.Respir.Dis., 141: A31.CrossRefGoogle Scholar
  4. Christie, P.E., Tagari, P., Ford-Hutchinson, A.W., Charleson, S., Chee, P., Arm, J.P., and Lee, T.H., 1991, Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects, Am.Rev.Respir.Dis., 143: 1025–1029.PubMedCrossRefGoogle Scholar
  5. Clark, J.D., Lin L-L, Kriz, R.W., Ramesha, C.S., Sultzman, L.A., Lin, A.Y., Milona, N., and Knopf, J.L., 1991, A novel arachidonic acid-selective cytosolic PLA2 contains a Caa+-dependent translocation domain with homology to PKC and GAP, Cell, 65: 1043–1051.PubMedCrossRefGoogle Scholar
  6. de Jong, E.M.G.J., van Vlijmen, I.M.M.J., Scholte, J.G.M., Buntinx, A., Friedman, B., Tanaka, W., van de Kerkhof, P.C.M., Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK-886) in psoriasis, Skin Pharmacol. submitted for publication.Google Scholar
  7. Dixon, R.A.F., Diehl, R.E., Opas, E., Rands, E., Vickers, P.J., Evans, J.F., Gillard, J.W., and Miller, D.K., 1990, Requirement of a 5-lipoxygenase activating protein for leukotriene synthesis, Nature 343: 282–284.PubMedCrossRefGoogle Scholar
  8. Ford-Hutchinson, A.W., 1990a, Arachidonic acid metabolism–enzymatic pathways. In “Eicosanoids and the Skin”, T. Ruzicka, Ed. pp. 3–22, CRC Press, Boca Raton, Florida.Google Scholar
  9. Ford-Hutchinson, A.W., 1990b, Leukotriene B4 in inflammation, Crit.Rev.Immunol., 10: 1–12.PubMedGoogle Scholar
  10. Ford-Hutchinson, A.W., Bray, M.A., Doig, M.V., Shipley, M.E., and Smith, M.J.H., 1980, Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes, Nature, 286: 264–265.PubMedCrossRefGoogle Scholar
  11. Fretland, D.J., Djuric, S.W., and Gaginella, T.S., 1990, Eicosanoids and inflammatory bowel disease: regulation and prospects for therapy, Prostaglandins Leukot. Essent. Fatty Acids, 41: 215–233.CrossRefGoogle Scholar
  12. Gaddy, J., Bush, R.K., Margolskee, D., Williams, V.C., and Busse, W., 1990, The effects of a leukotriene D4 (LTD4) antagonist (MK-571) in mild to moderate asthma, J. Allergy Clin Immunol., 85: 197 (Abstr).Google Scholar
  13. Gillard, J., Ford-Hutchinson, A.W., Chan, C., Charleson, S., Denis, D., Foster, A., Fortin, R, Leger, S., McFarlane, C.S., Morton, H., Piechuta, H., Riendeau, D., Rouzer, C.A., Rokach, J., Young, R., MacIntyre, D.E., Peterson, L., Bach, T., Eiermann, G., Hopple, S., Humes, J., Hupe, L., Luell, S., Metzger, J., Meurer, R., Miller, D.K., Opas E., and Pacholok S., 1989, L-663,536 (MK-886)(3-[1-(4-chlorobenzyl)-3-tbutyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor, Can.J.Physiol.Pharmacol. 67: 456–464.PubMedCrossRefGoogle Scholar
  14. Hendeles, L., Davison, D., Blake, K., Harman, E., Cooper, R., and Margolskee, D., 1990, Leukotriene D4 is an important mediator of antigen-induced bronchoconstriction: attenuation of dual response with MK-571, a specific LTD4 receptor antagonist, J.Allergy Clin.Immunol., 85: 197 (Abstr).Google Scholar
  15. Hui, K.P., and Barnes, N.C., 1991, Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist, Lancet, 337: 1062–1063.PubMedCrossRefGoogle Scholar
  16. Israel, E., Dermarkarian, R., Rosenberg, M, Sperling, R., Taylor, G., Rubin, P., and Drazen, J.M., 1990, The effects of 5-lipoxygenase inhibitor on asthma induced by cold, dry air, N.Engl.J.Med. 323: 1740–1744.PubMedCrossRefGoogle Scholar
  17. Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A.W., Frenette, R., Gauthier, J-Y., Leger, S., Masson, P., McFarlane, C.S., Piechuta, H., Rokach, J., Williams, H., Young, R.N. DeHaven, R.N., and Pong, S.S., 1989, Pharmacology of L-660,711 (MK-571): A novel, potent and selective leukotriene D4 receptor antagonist, Can.J.Physiol.Pharmacol., 67: 17–28.PubMedCrossRefGoogle Scholar
  18. Kips, J., Joos, G., DeLepeleire, I., Margolskee, D., Buntinx, A., Pauwels, R., and Van der Straeten, M. MK-571: a potent antagonist of LTD4 induced bronchoconstriction in man. Am.Rev.Respir.Dis. (in press).Google Scholar
  19. Knapp, H.R., 1990, Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor, N.Engl.J.Med., 323: 1745–1748.PubMedCrossRefGoogle Scholar
  20. Laursen, L.S., Naesdal, J., Bukhave, K., Lauritsen, K., and Rask-Madsen, J., 1990, Selective 5-lipoxygenase inhibition in ulcerative colitis, Lancet, 335: 683–685.PubMedCrossRefGoogle Scholar
  21. Lewis, M.A., Mong, S., Vessella, R.L., and Crooke, S.T., 1985, Identification and characterization of leukotriene D4 receptors in adult and fetal human lung, Biochem.Pharmacol., 34: 4311–4317.PubMedCrossRefGoogle Scholar
  22. Manning, P.J., Watson, R.M., Margolskee, D.J., Williams, V.C., Schwartz, J.I., and O’Byrne, P.M., 1990, Inhibition of exercise-induced bronchoconstriction by MK571, a potent leukotriene D4 receptor antagonist, N.Engl.J.Med., 323: 1736–1739.PubMedCrossRefGoogle Scholar
  23. Margolskee, D., Bodman, S., Dockhorn, R., Israel, E., Kemp, J., Mansmann, H., Minotti, D.A., Spector, S., Snicker, W., Tinkelman, D., Townley, R., Winder, J., and Williams, V., 1991, The therapeutic effects of MK-571, a potent and selective leukotriene (LT) D4 receptor antagonist, in patients with chronic asthma, J.Allergy Clin.Immunol., 87: 309 (Abstr).Google Scholar
  24. Miller, D.K., Gillard, J.W., Vickers, P.J., Sadowski, S., Léveillé, C., Mancini, J.A., Charleson, P., Dixon, R.A.F., Ford-Hutchinson, A.W., Fortin, R., Gauthier, J-Y., Rodkey, J., Rosen, R., Rouzer, C., Sigal, I.S., Strader, C.D., and Evans, J.F., 1990, Identification and isolation of a membrane protein necessary for leukotriene production, Nature, 343: 278–281.PubMedCrossRefGoogle Scholar
  25. Piper, P.J., 1985, Leukotrienes: potent mediators of airway constriction, Int.Arch.Allergy Appl.Immun., 76:(Suppl.1)43–48.Google Scholar
  26. Rouzer, C.A., and Kargman, S., 1988, Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187, J.Biol.Chem., 263: 1098010988.Google Scholar
  27. Samuelsson, B., 1983, Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation, Science, 220: 568–575.PubMedCrossRefGoogle Scholar
  28. Smith, L.J., Geller, S., Ebright, L., Glass, M. and Thyrum, P.T., 1990, Inhibition of leukotriene (LT) DQ induced bronchoconstriction in asthmatic subjects by the oral LTD4 receptor antagonist ICI 204,219, Am.Rev.Respir.Dis., 141: A33.CrossRefGoogle Scholar
  29. Tanaka, W., Dallob, A., Winchell, G., Kline, W., Spector, R., Bjornsson, T., and DeSchepper, P., 1990, Safety, pharmacokinetics and leukotriene B4 (LTB4) inhibition after MK-886 administration in normal male volunteers, Am.Rev.Respir.Dis., 141: A32.Google Scholar
  30. Taylor, G.W., Taylor, I., Black, P.,Maltby, N.H., Turner, N., Fuller, R.W., and Dollery, C.T., 1989, Urinary leukotriene E4 after antigen challenge in acute asthma and allergic rhinitis, Lancet, I: 584–588.CrossRefGoogle Scholar
  31. Taylor, I.K., O’Shaughnessy, K.M., Fuller, R.W., and Dollery, C.T., 1991, Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects, Lancet, 337: 690–694.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • A. W. Ford-Hutchinson
    • 1
  1. 1.Merck Frosst Centre for Therapeutic ResearchQuebecCanada

Personalised recommendations